A drug cut pancreas-attack rates by 91% vs placebo among patients with recent attacks
Arrowhead's plozasiran reduced acute pancreatitis events by 91% in severe hypertriglyceridemia patients with recent attacks. ARO-DIMER-PA showed LDL-C reductions up to 65% and triglyceride reductions up to 78%. Data presented at AHA Scientific Sessions 2026.
How this was made
The 30-second read
Why it matters
The data show substantial reductions in LDL‑C, triglycerides, PCSK9, and APOC3, plus a 91% drop in acute pancreatitis events among recent‑attack patients, suggesting a differentiated therapeutic profile.
Market read
First‑report of strong early‑stage efficacy could drive short‑term buying interest in ARWR and influence peer biotech valuations.
What to watch
Small patient numbers and lack of a control arm in extension study could limit confidence; competition from other TG‑lowering agents.
Background
Arrowhead Pharmaceuticals (ARWR) disclosed interim results from its ARO-DIMER-PA (plozasiran) program at the American Heart Association Scientific Sessions 2026, targeting severe hypertriglyceridemia and familial chylomicronemia syndrome.
Ticker impact
Arrowhead Pharmaceuticals presented interim Phase 1/2a data for its investigational siRNA ARO-DIMER-PA (plozasiran) showing up to 91% reduction in acute pancreatitis events in severe hypertriglyceridemia patients.
likely upward pressure as investors price in potential first‑in‑class therapy.
Data are first‑report, statistically strong reductions in pancreatitis events and lipid markers; no comparable therapy exists, creating a clear catalyst.
Market effects
May boost interest in lipid‑lowering siRNA platforms and broader biotech sector focused on rare metabolic diseases.
Limited to US biotech investors; no immediate regional effect.
Potential global relevance if therapy advances, but short‑term impact confined to Arrowhead.
Counterpoint
Early‑stage data may not translate to later‑stage efficacy; safety signals could emerge, tempering upside.
Key entities
- CompanyArrowhead Pharmaceuticals
US‑listed biotech developing siRNA therapeutics.
- OrganizationAmerican Heart Association
Venue where the data were presented.
